272. 進行性骨化性線維異形成症 Fibrodysplasia ossificans progressiva Clinical trials / Disease details


臨床試験数 : 39 薬物数 : 38 - (DrugBank : 7) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05090891
(ClinicalTrials.gov)
May 5, 20228/10/2021To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)Drug: INCB000928;Drug: placeboIncyte CorporationNULLRecruiting12 Years99 YearsAll60Phase 2United States;Australia;Brazil;Canada;Chile;China;France;Germany;Italy;Korea, Republic of;Mexico;Netherlands;South Africa;Spain;Turkey;United Kingdom;Russian Federation
2EUCTR2021-002286-17-FR
(EUCTR)
19/04/202222/10/2021A Phase 2, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study toEvaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva Fibrodysplasia ossificans progressiva
MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Code: INCB000928
Other descriptive name: INCB000928 fumarate dihydrate
Incyte CorporationNULLNot RecruitingFemale: yes
Male: yes
60Phase 2United States;France;Canada;Brazil;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Korea, Republic of
3EUCTR2021-002286-17-DE
(EUCTR)
04/11/2021A Phase 2, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans ProgressivaA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study toEvaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva Fibrodysplasia ossificans progressiva
MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Code: INCB000928
Other descriptive name: INCB000928 fumarate dihydrate
Incyte CorporationNULLNAFemale: yes
Male: yes
60Phase 2France;United States;Canada;Brazil;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Korea, Republic of